Modified Bacterial Collagen Proteins for Cross-Linking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant collagen-like proteins face challenges in achieving stability and functionality similar to native animal collagens, particularly due to the lack of hydroxyproline and mammalian crosslinking sites, which affects their interactions and applications in biomedical and non-medical uses.
Innovation Solution
Modification of bacterial collagen-like proteins by incorporating reactive amino acids such as cysteine and tyrosine within or adjacent to the triple-helical domains to introduce chemical reactive sites, allowing for specific functional modifications and cross-linking without denaturation or degradation during production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If bacterial collagen-like proteins are produced without post-translational modification, then production complexity is reduced, but stability and functionality are insufficient compared to native animal collagens
Solution Approach 1:
The patent applies preliminary action by incorporating reactive amino acid residues (cysteine, tyrosine, tryptophan) directly into the bacterial collagen-like protein sequence during gene synthesis, before the protein is expressed. This pre-programming of reactive sites eliminates the need for post-translational modification while ensuring the protein has the necessary functionality for cross-linking and stability from the moment of production
Solution Approach 2:
The patent changes the amino acid composition parameters of the bacterial collagen-like protein by specifically incorporating reactive residues at defined positions within the triple-helical domain. This parameter modification allows the protein to achieve mammalian collagen-like stability and cross-linking capability without requiring complex post-translational modification systems
2Adaptability or versatility
If reactive amino acids are incorporated into triple-helical domains, then site-specific cross-linking and modifications are enabled, but protein structure complexity increases
Solution Approach 1:
The patent applies local quality by incorporating reactive amino acid residues at specific, localized positions within the triple-helical domain rather than uniformly throughout the protein. This targeted approach enables site-specific cross-linking and modifications only where needed, maintaining the overall simplicity of the bacterial protein while adding functionality at critical locations
Solution Approach 2:
The patent creates a composite structure by combining the simple bacterial collagen-like protein backbone with strategically placed reactive amino acid residues. This composite approach allows the protein to exhibit both the simplicity of bacterial expression and the enhanced functionality of site-specific cross-linking, effectively merging the advantages of different protein systems
3Reliability
If animal-derived collagen is extracted and modified, then biological functionality is maintained, but transmissible disease risk and lot-to-lot variability increase
Solution Approach 1:
The patent applies copying by synthesizing bacterial collagen-like proteins with sequences that mimic the functional characteristics of mammalian collagens, including the incorporation of reactive amino acids that enable cross-linking. This synthetic copy achieves the desired biological functionality without using actual animal-derived materials, thereby eliminating disease transmission risks and batch variability
Solution Approach 2:
The patent uses a disposable, synthetic bacterial protein system that replaces expensive, variable animal-derived collagen. The bacterial protein can be produced recombinantly with consistent, defined sequences, eliminating the need for complex extraction and modification processes while providing reliable, reproducible results without animal disease risks
Data Source
AI summary
The present disclosure relates to recombinant or synthetic collagen-like proteins comprising at least one triple-helical domain and wherein the collagen-like protein is modified compared to a native bacterial collagen-like sequence.